- CytoSorbents ( NASDAQ: CTSO ) said the Israeli Ministry of Health approved national reimbursement for CytoSorb in certain cardiac surgery indications which is expected to take effect in 2023.
- The company added that once the policy revision is completed, public hospitals are expected to receive reimbursement for CytoSorb for the particular applications.
- The company noted that CytoSorb removes a variety of antithrombotic drugs and inflammatory mediators intraoperatively during cardiac surgery. CytoSorb is an extracorporeal blood purification method to reduce excess inflammatory mediators and elevated levels of bilirubin and myoglobin.
- CTSO +9.84% to $2.01 premarket Aug. 17
For further details see:
CytoSorbents stock rises 10% as Israel approves coverage for CytoSorb system